<DOC>
	<DOCNO>NCT02212327</DOCNO>
	<brief_summary>The investigator ' overarch goal improve long-term outcome end stage renal disease ( ESRD ) patient . In study focus specifically patient receive peritoneal dialysis ( PD ) . Volume regulation PD patient related hypertension , heart failure , nutritional status , survival . Salt ( NaCl ) body 's ion transport target normally regulate volume via kidney ; however , hemodialysis ( HD ) patient dialyser PD patient peritoneal membrane , must serve purpose . Determining volume status PD patient easy monitoring sodium ( Na+ ) difficult still . The investigator develop novel , noninvasive approach problem involve 23Na+ magnetic resonance imaging ( Na-MRI ) . Na+ store bound proteoglycans mostly skin . Our technique measure Na+ skin skeletal muscle . In study , propose apply novel technique PD patient . Aim 1 . To determine Na+ store PD patient , compare Na+ store normal control use Na-MRI technique , correlate Na+ store Na-MRI multifrequency bioimpedance measurement cross-sectional clinical data . Hypothesis : Na+ store increase PD patient compare normal control ; increase PD patient volume expansion patient high soluble vascular endothelial growth factor receptor-3 ( sFlt-4 ) level . Aim 2 . To determine utility Na-MRI assessment preserve residual renal function PD patient . Hypothesis : Extracellular volume expansion measure multifrequency bioimpedance find utility predict preservation residual renal function PD patient . The investigator hypothesize Na+ store determine 23Na-MRI fulfill function inversely , rather directly , relate .</brief_summary>
	<brief_title>Testing Tissue Sodium Stores CAPD Patients—Aims 1 &amp; 2</brief_title>
	<detailed_description />
	<mesh_term>Kidney Failure , Chronic</mesh_term>
	<criteria>Both subject group : Age 18 80 year ; BMI &lt; 40 ; Ability give informed consent ; Life expectancy great 6 month . PD subject : On peritoneal dialysis great 3 month ; Using glucose lactatebuffered PD solution consistent glucose exposure ; Stable peritoneal prescription ( Kt/V &gt; 1.7 Tccr &gt; 50 ml/week/1.73 m2 ) . Control subject : Estimated glomerular filtration rate ( GFR ) ≥ 60 ml/min/1.73m2 ; No proteinuria . Exclusion Criteria ( subject group ) : Pregnancy ; Intolerance study protocol ; Severe , unstable , active , chronic inflammatory disease ( congestive heart failure—NY Class IV , active infection , active connective tissue disorder , active cancer cancer history prior 5 year , HIV , liver disease , include active chronic hepatitis B C ) ; Active inflammatory condition [ systemic lupus erythematosus ( SLE ) , rheumatoid arthritis ( RA ) , minimal change disease ( MCD ) ] ; Patients prescribe treated spironolactone ; History cirrhosis ; Poor compliance dialysis prescription .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>Na+ MRI</keyword>
	<keyword>salt store</keyword>
</DOC>